The CCTG PA.7 trial: A randomized phase II study of gemcitabine and nab-paclitaxel vs. gemcitabine, nab-paclitaxel, durvalumab, and tremelimumab as 1st line therapy in metastatic pancreatic ductal adenocarcinoma (PDAC).

被引：2

作者：

Renouf, Daniel John

Kavan, Petr

Dhani, Neesha C.

Jonker, Derek J.

Wei, Alice Chia-chi

Hsu, Tina

Tang, Patricia A.

Graham, Barbara

机构：

[1] BC Canc Agcy, Vancouver, BC, Canada

[2] McGill Univ, Montreal, PQ, Canada

[3] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[4] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada

[5] Univ Toronto, Toronto Gen Hosp, Dept Surg, Toronto, ON, Canada

[6] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada

[7] Tom Baker Canc Clin, Calgary, AB, Canada

[8] Queens Univ, Kingston, ON, Canada

[9] Canadian Canc Trials Grp, Kingston, ON, Canada

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.TPS4149

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4149

引用

页数：6